2 Topic Commentaries

Multiple Myeloma, Neoplasms, Bortezomib

• 

  Shaji Kumar, MD

  Hematology/Oncology

  •

  Mayo Clinic

  "Previous, small, single arm studies initially suggested that carfilzomib, a next generation proteasome inhibitor may give better results than Bortezomib in the initial treatment of multiple myeloma," "This phase 3 trial, was designed to examine if Carfilzomib would be more effective than Bortezomib, when combined with Lenalidomide and Dexamethasone for treatment of newly diagnosed myeloma."

  Source
• 

  Saad Z. Usmani, MD, MBA, FACP, FASCO

  Memorial Sloan Kettering Cancer Center

  •

  Memorial Sloan Kettering Cancer Center

  "The deeper responses translated to a significant, 43% lower risk of disease progression or death for patients in the D-VRd group compared to those in the VRd group," "The trial results support D-VRd becoming the new standard of care for patients with newly diagnosed transplant ineligible or transplant-deferred multiple myeloma."

  Source